Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Global Stock · Janus Henderson

Janus Henderson Global Life Sciences Fund Class A (JFNAX)

Ticker JFNAX · · Holdings as of Jun 30, 2026

Expense ratio
1%$100/yr per $10k
Net assets
$5.8Ball share classes
Holdings
108

Bottom line

Is JFNAX a good fund? The bottom line

JFNAX is the Class A share class of Janus Henderson Global Life Sciences Fund, a managed global stock mutual fund from Janus Henderson.

It charges 1% — about $100 a year on every $10,000 invested, more expensive than 58% of global stock funds we track.

With $5.8 billion in net assets and 108 holdings, its largest position is Eli Lilly & Co. (9.4%) and the top 10 make up 42.4% of the portfolio.

This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.

What to watch

  • Front-end sales load up to 5.75%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What JFNAX invests in

Janus Henderson Global Life Sciences Fund seeks long-term growth of capital.

The Fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that portfolio management believes have a life science orientation. In the Funds pursuit of companies with a life science orientation, the Fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the life sciences sector, which may include companies in the following industry groups: pharmaceuticals; biotechnology; health care services; agriculture; cosmetics/personal care; and medical devices. Generally speaking, the life sciences relate to maintaining or improving quality of life. So, for example, companies with a life science orientation include companies engaged in research, development, production, or distribution of…

From the fund's prospectus (filed Jan 28, 2026).

What JFNAX costs

On a $10,000 investment, JFNAX's 1% expense ratio costs about $100 a year. The prospectus estimates $1,729 in total costs over 10 years (assuming 5% annual returns). The median global stock fund charges 0.95%.

See the full JFNAX fee table →

JFNAX top 10 holdings

#Holding% of fund
1Eli Lilly & Co.9.41%
2Johnson & Johnson7.09%
3AbbVie, Inc.4.67%
4UnitedHealth Group, Inc.4.54%
5AstraZeneca plc3.93%
6Revolution Medicines, Inc.3.02%
7Argenx SE2.63%
8Novartis AG2.56%
9Thermo Fisher Scientific, Inc.2.33%
10Praxis Precision Medicines, Inc.2.19%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 42.4% of the fund. See all top 25 holdings and asset mix →

Alternatives to JFNAX

More funds like JFNAX →

JFNAX FAQ

What is the expense ratio of JFNAX?
JFNAX's expense ratio is 1%, which works out to about $100 a year for every $10,000 invested. The prospectus estimates total costs of $1,729 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is JFNAX a good investment?
It depends on your goals, but the data points to: front-end sales load up to 5.75%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does JFNAX hold?
JFNAX's largest holdings are Eli Lilly & Co. (9.4%), Johnson & Johnson (7.1%), AbbVie, Inc. (4.7%), UnitedHealth Group, Inc. (4.5%), AstraZeneca plc (3.9%). It holds 108 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
Does JFNAX have a sales load?
Yes. JFNAX has a maximum front-end sales charge of 5.75%.
Who manages JFNAX?
JFNAX is offered by Janus Henderson through Janus Investment Fund.